Mathematical modeling of radiotherapy and its impact on tumor interactions with the immune system

• Published in: Neoplasia (New York, N.Y.) Vol. 28; p. 100796
• Main Authors: Bekker, Rebecca Anne, Kim, Sungjune, Pilon-Thomas, Shari, Enderling, Heiko
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2022; Neoplasia Press; Elsevier
• Subjects: Combined Modality Therapy; Humans; Immune System; Immunotherapy; Immunotherapy - methods; Mathematical model; Models, Theoretical; Neoplasms; Original Research; Personalized oncology; Radiotherapy; Tumor immune interactions; Tumor Microenvironment; BED; OAR; RT; LQ; PSI; RSI; TIME; IT; Radiotherapy; GARD; SFRT; TFRT; APC; Personalized oncology; TAA; Immunotherapy; PD-L1; Tumor immune interactions; CTLA-4; Mathematical model; PD-1; DAMP
• ISSN: 1476-5586; 1522-8002; 1476-5586
• DOI: 10.1016/j.neo.2022.100796

Radiotherapy is a primary therapeutic modality widely utilized with curative intent. Traditionally tumor response was hypothesized to be due to high levels of cell death induced by irreparable DNA damage. However, the immunomodulatory aspect of radiation is now widely accepted. As such, interest into the combination of radiotherapy and immunotherapy is increasing, the synergy of which has the potential to improve tumor regression beyond that observed after either treatment alone. However, questions regarding the timing (sequential vs concurrent) and dose fractionation (hyper-, standard-, or hypo-fractionation) that result in improved anti-tumor immune responses, and thus potentially enhanced tumor inhibition, remain. Here we discuss the biological response to radiotherapy and its immunomodulatory properties before giving an overview of pre-clinical data and clinical trials concerned with answering these questions. Finally, we review published mathematical models of the impact of radiotherapy on tumor-immune interactions. Ranging from considering the impact of properties of the tumor microenvironment on the induction of anti-tumor responses, to the impact of choice of radiation site in the setting of metastatic disease, these models all have an underlying feature in common: the push towards personalized therapy.